- Home
- UHAL vs JAZZ Comparison
UHAL vs JAZZ Comparison
Compare UHAL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHAL | JAZZ |
|---|---|---|
| Founded | 1945 | 2003 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.4B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | UHAL | JAZZ |
|---|---|---|
| Price | $51.26 | $169.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $207.19 |
| AVG Volume (30 Days) | 177.9K | ★ 658.6K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $6.58 | $6.19 |
| Revenue Next Year | $4.23 | $6.46 |
| P/E Ratio | $78.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.84 | $95.49 |
| 52 Week High | $73.53 | $182.99 |
Technical Indicators
Market Signals| Indicator | UHAL | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 56.80 |
| Support Level | $47.84 | $165.36 |
| Resistance Level | $51.74 | $168.93 |
| Average True Range (ATR) | 2.09 | 3.66 |
| MACD | -0.38 | 0.37 |
| Stochastic Oscillator | 28.61 | 86.64 |
Price Performance
Historical ComparisonAbout UHAL U-Haul Holding Company
U-Haul Holding Co is an American moving truck, trailer, and self-storage rental company. The company also provides moving boxes, packing supplies, LPG (propane) refills, trailer hitch and wiring installation, storage container rentals, and other services. It has three reportable segments Moving and Storage, Property and Casualty Insurance, and Life Insurance. The majority of its revenue comes from the Moving and Storage segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.